

Genetic Technologies, Qiagen to establish Centre of Excellence facility in Australia

03 February 2023 | News

QIAGEN will support the enhancement of GTG capabilities through software, hardware, consumable and technical solutions

Australian firm Genetic Technologies Limited (GTG), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, has formed a strategic alliance with Qiagen, a global leader in molecular testing with operations in 35 countries.

The alliance will establish and develop a 'Centre of Excellence' facility in Australia initially servicing Australia and New Zealand with potential for expansion, showcasing the Life Science and Diagnostics expertise of both organisations throughout the region. The partnership will further enhance GTG's reputation as a regional leader in precision medicine in predicative and consumer genomics, utilising Qiagen technologies.

The relationship is expected to open a wide range of new commercial opportunities for GTG with enhanced automation capability and increased capacity supporting long-term revenue growth. Additionally, this initiative will unlock the Australian reimbursable market for all testing categories, including the geneType hereditary cancer test.

This will make the geneType Breast, Ovarian and Colorectal cancer tests the most comprehensive offering in the market later in 2023. Gaining reimbursement coverage for geneType cancer assessment tests is expected to accelerate the adoption of these tests by General Practice clinics where patients are able to undertake the test with minimal out-of-pocket expenses.